FDA approves buprenorphine implant for opioid dependence

摘要

The FDA approved buprenorphine (Probuphine), the first subdermal implant for long-term maintenance treatment of opioid dependence. Probuphine, a partial opioid agonist, is designed to provide a constant, low-level dose of buprenorphine for 6 months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine as part of a complete treatment program that includes counseling and psychosocial support.